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Photoactivated cell-killing involving a low
molecular weight, donor–acceptor
diphenylacetylene†
David R. Chisholm,a Rebecca Lamb,b Tommy Pallett,bc Valerie Aﬄeck,d
Claire Holden,ab Joanne Marrison,e Peter O'Toole,e Peter D. Ashton,e
Katherine Newling,e Andreas Steﬀen,f Amanda K. Nelson,f Christoph Mahler,f
Roy Valentine,g Thomas S. Blacker,h Angus J. Bain, h John Girkin, *c
Todd B. Marder, *f Andrew Whiting *a and Carrie A. Ambler *b
Photoactivation of photosensitisers can be utilised to elicit the production of ROS, for potential therapeutic
applications, including the destruction of diseased tissues and tumours. A novel class of photosensitiser,
exempliﬁed by DC324, has been designed possessing a modular, low molecular weight and ‘drug-like’
structure which is bioavailable and can be photoactivated by UV-A/405 nm or corresponding two-
photon absorption of near-IR (800 nm) light, resulting in powerful cytotoxic activity, ostensibly through
the production of ROS in a cellular environment. A variety of in vitro cellular assays conﬁrmed ROS
formation and in vivo cytotoxic activity was exempliﬁed via irradiation and subsequent targeted
destruction of speciﬁc areas of a zebraﬁsh embryo.
1 Introduction
The generation and modulation of reactive oxygen species
(ROS) is of huge importance in the control, maintenance,
defence and death of both eukaryotic and prokaryotic cells.1,2
Indeed, ROS are produced by a number of biochemical
processes in order to modulate cellular behaviour; however,
they can also be generated by the action of the excited states of
chemical compounds known as photosensitisers formed
through absorption of light.3 Light activation of a photo-
sensitiser typically involves photoexcitation from the ground
state (S0) to a singlet excited state (S1), which can then undergo
intersystem-crossing to a triplet excited state (T1).4,5 ROS
formation can then occur via two pathways, type I and type II. A
type I process can occur either from the S1 or the T1 state of the
photosensitiser and involves either hydrogen or electron
transfer between the excited photosensitiser and a substrate.
The resulting radicals can react with molecular oxygen (3O2),
typically producing ROS species such as superoxide (O2c
) and
hydroxyl radicals (OHc). A type II process involves direct energy
transfer from the longer-lived T1 state of the excited photo-
sensitiser to 3O2, generating singlet oxygen (
1O2).6
In a cellular context, these oxygen-derived species elicit
a variety of modulatory eﬀects depending on the rate and extent
of their production; at high concentrations apoptosis is
observed, while at low concentrations a stimulatory response is
oen evident.7–9 Both pathways hold considerable therapeutic
potential, but the majority of photosensitisers in the clinic are
used for photodynamic therapy (PDT), in which a photo-
sensitiser is excited near/inside a particular target tissue or
condition (e.g. microbial infections, neoplasias, tumors, etc.),
causing the generation of large quantities of ROS and subse-
quent destruction of that tissue.3,10 Photosensitisers clinically
approved for PDT of various cancers include Photofrin® (Fig. 1)
and 5-aminolaevulinic acid, which is metabolized to the active
photosensitiser, protoporphyrin IX.11–13
However, these compounds exhibit inadequate pharmaco-
logical properties including poor dosage control due to the
requirement for metabolic processing, and extremely long bio-
logical half-lives, which causes skin photosensitivity for weeks
aer treatment.3 Indeed, the vast majority of recently reported
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photosensitizers are high molecular weight, hydrophobic, oen
metal-containing porphyrin, chlorin and phthalocyanine scaf-
folds.14 The large size of these molecules has a signicant and
negative eﬀect on cell permeability and diﬀusion rate into and
out of the cell, and non-specic cell death is another major
problem due to both the inability to target the compounds
locally and issues with accumulation in oﬀ-target tissues and
organs.3,15,16 Therefore, the inherent properties of these struc-
tures make them eﬃcient photosensitisers, but far from ideal as
therapeutics. A genetically encoded variant of green uorescent
protein (GFP), KillerRed (Fig. 1), is also a potent photo-
sensitiser; however, the requirement for genetic modication
probably makes KillerRed unviable for clinical PDT, though the
method has great potential for biological studies.17 Due to these
drawbacks, ne control of the release of ROS in a therapeutic
context is not possible with current photosensitisers. Conse-
quently, there is a major need for novel compounds and ROS
generation mechanisms that are able to elicit an entirely
controlled either destructive or proliferative cellular response
based on the requirements of the disease, and indeed, the
temporal requirements of clinical treatment. In this paper, we
report a new class of low molecular weight, ‘drug-like’
compounds which exhibit the potential to elicit such
controlled cytotoxic activity.
2 Results and discussion
2.1 Synthesis
Inspired by our work on the design, synthesis and applications
of synthetic retinoids for controlling cellular development,18–25
we recently designed uorescent analogues of such compounds
for use in uorescence-based biophysical studies.26,27 It is
known that the addition of a strong p-donor (–NR2) and strong
p-acceptor (–CO2R) to a diphenylacetylene scaﬀold results in
eﬃcient charge transfer from the donor moiety to the acceptor
moiety upon photoexcitation.28–33 The resulting structures
exhibit strong, solvatochromatic uorescence with signicant
bathochromic shis in absorption and emission spectra in
polar media due to the eﬃcient formation of intramolecular
charge transfer (ICT) excited states, and we were interested in
synthesising a range of such compounds that incorporated
highly lipophilic and electron rich tetrahydroquinoline donor
structures34,35 for use in cellular imaging studies. One such
compound, DC324, was synthesised by the coupling of 6-iodo-
tetrahydroquinoline (reported previously34) 5, with acceptor
alkyne 4 (Fig. 2 and 3).
Compound 4 was synthesised via a four-step approach,
beginning with diazotisation of 4-iodoaniline to give the bench-
stable diazonium tetrauoroborate salt 1. This was suitably
reactive under Heck–Matsuda conditions,36 enabling eﬀective
conversion to the desired cinnamate 2 in 75% yield with
complete E-selectivity (crystal structure shown in the ESI†).
Sonogashira coupling with trimethylsilylacetylene gave the
protected alkyne 3,37 which was initially deprotected using
K2CO3 in MeOH/DCM to give the target acceptor alkyne 4. While
these conditions did remove the TMS protecting group, it was
also found that the presence of traces of EtOH in the
commercial grade MeOH used for the reaction caused eﬃcient
transesterication to the corresponding ethyl ester. To
circumvent this, deprotection using TBAF in THF at 20 C
cleanly provided 4 with the methyl ester intact. Sonogashira
coupling of acceptor 4 with donor 5 proceeded with complete
conversion to the desired coupled product which, upon
saponication, gave the target compound DC324 in a 67% yield
over the three steps. We have also recently reported the
Fig. 1 Comparison of the characteristics of DC324 and DC473 with those of existing photosensitisers, KillerRed and Photofrin®.
Fig. 2 Synthesis of acceptor alkyne 4.
Fig. 3 Coupling of acceptor alkyne 4 and donor tetrahydroquinoline 5
(ref. 34) to give DC324.
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synthesis, uorescence properties and cellular localisation
behaviour of DC473 (Fig. 1), a close analogue of DC324 with
a methyl cinnamate acceptor group and N-propargyl tetrahy-
droquinoline donor which can be utilised for dual uorescence/
Raman imaging in cells.38
2.2 Photophysical characterisation
Photophysical and computational studies showed that DC324
exhibits two strong absorptions (Table 1, Fig. 4A) with extinc-
tion coeﬃcients of ca. 27 000–41 000 M1 cm1 in the UV and
violet regions, respectively, both arising from the formation of
ICT excited states. Consequently, a solvatochromatic absorption
was observed, wherein polar solvents give rise to a hyp-
sochromic shi, which indicates that the ground state S0 is
more polar than the Franck–Condon S1 excited state. However,
even more impressive is the highly solvatochromatic uores-
cence (Table 1, Fig. 4B), with quantum yields of up to 0.92 in
non-polar solvents such as toluene,28,29 and an emission lifetime
of 2.0 ns. However, in more polar solvents, such as EtOH, DMSO
or CH2Cl2, a second excited state process occurs, giving rise to
the reproducible observation of a secondary decay starting
around 500 ps aer the laser pulse, which was observed on
several spectrophotometers and is not an artifact of a particular
instrument. DC324 shows similar photophysical properties
when compared to DC473 (ref. 38) although DC324 exhibits
bathochromic shis in absorption and emission in non-polar
solvents, presumably due to the increased donor strength of
the N-iPr moiety in comparison to the N-propargyl group of
DC473. We also measured the two-photon absorption (TPA)
spectra of DC324 and DC473 in toluene (Fig. 4C), and note the
TPA cross-sections of around 500 GM at 790 nm which are
impressive for such a small dipolar molecule. Comparing with,
for example, a simple dimethylamino donor/dimesitylboryl
acceptor-substituted diphenylacetylene,39 which has similar
absorption properties in toluene, the emission spectra ofDC324
and DC473 are somewhat red-shied, and the TPA cross-section
is ca. 2.5 times higher for the latter two compounds. This can
likely be attributed to a combination of the increased donor
strength of the rigidied tetrahydroquinoline-based moiety and
the extension of the conjugation length via the alkene unit in
DC324 and DC473. The TPA cross-section is the typical measure
of the eﬃciency with which a compound absorbs two photons;
for one-photon absorption, the eﬃciency of absorption is typi-
cally reported as an extinction coeﬃcient. In a cellular and
biological imaging context, a greater TPA cross-section allows
lower laser powers to be used to excite larger numbers of
Table 1 Photophysical properties of DC324 in a variety of solvents,
MeCy ¼ methylcyclohexane
Solvent labs(max)/nm, (3/M
1 cm1) lem(max)/nm f s/ns
MeCy 394, 296 434, 460 — —
Toluene 395(30 600), 297(27 700) 498 0.92 2.0
MeCN 385(31 200), 295(28 000) 513 0.04 —
EtOH 366(41 100), 294(30 800) 533 0.10 —
DMSO 380(32 500), 297(32 200) 512 0.30 —
H2O 385, 298 562 — —
CH2Cl2 403, 301 622 — —
Fig. 4 (A) Absorption spectra ofDC324 in a variety of solvents and electron density diﬀerence plots for the two observedmajor absorption bands
S0/ S1 (low energy) and S0/ S2 (high energy) obtained from TD-DFT calculations at the M06-D3-BJ/def2-TZVP level of theory. (B) Emission
spectra of DC324 in a variety of solvents. (C) Two-photon absorption spectra of DC324 and DC473 in toluene. (D) HaCaT keratinocytes treated
with 10 mM DC324 for 30 min, prior to irradiation. (E) HaCaT keratinocytes treated with 10 mM DC324 after multiple short irradiations with
405 nm, 12 hours after initial imaging.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 4673–4683 | 4675
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molecules, thus reducing the risk of thermal damage to the
tissue and also enables deeper penetration in more scattering
tissue samples.
The most interesting nding, however, was that when DC324
and DC473 were irradiated with UV-A (350–390 nm) light in
cultured epithelial cells, rapid cell death was observed that was,
possibly, consistent with the production of large amounts of
ROS (Fig. 4D/E).
2.3 In vitro characterisation
To investigate this observed cell death we performed a range of
cellular and cuvette-based experiments to understand local-
isation and mode of action. According to confocal uorescence
microscopy, DC324 was found to exhibit non-specic local-
isation in non-polar, membrane-rich environments, including
mitochondria (Pearson's correlation with MitoTracker Red, R ¼
0.81) and other organelles (Fig. 5A).38 This nding was sup-
ported by the fact that the emission peaks (lex ¼ 405 nm)
detected at 460–490 nm were similar to cuvette-based
measurements in non-polar solvents such as toluene or meth-
ylcyclohexane. However, the observed emission wavelength
varied subtly (Fig. 5B) according to the cellular environment, as
a result of the solvatochromatic behaviour of the compound.
We next utilised the redox reactive dye CellRox,40 which
uoresces in response to oxidation by ROS, to determine
whether ROS is produced either by, or in response to, in cellulo
photoactivation of DC324. Whereas in the absence of the
compound no CellRox uorescence (and no cell death) was
observed, DC324-treated cells subsequently activated with
405 nm light exhibited a strong CellRox uorescence signal with
a steady increase immediately following irradiation, particularly
in intracellular organelles (Fig. 6). Similar behaviour was
observed in DC473-treated cells and, therefore, this initially
suggested that the compounds may act as photosensitisers to
elicit ROS formation in cells.
Because of the structural relationship with retinoids such as
all-trans-retinoic acid (ATRA) and other synthetic retinoids,20 we
were interested to determine whether retinoids, in general,
elicit ROS production when cells are treated with light. We,
therefore, chose EC23 (Fig. 7A),18 an analogue of DC324 and
DC473 with retinoid biochemical activity but no absorption or
photoactivity at 405 nm (since it lacks the amine donor func-
tionality), to act as a negative control. In these experiments,
treatment of cells with EC23 and subsequent irradiation did not
cause activation of CellRox nor any observable cell death
(Fig. 7B). It was, therefore, clear that the photophysical prop-
erties of DC324 and DC473, i.e. the ability to absorb light of
405 nm due to the addition of strong p-donor and extended p-
acceptor moieties, were mandatory to initiate cell death upon
photoactivation rather than an inherent biochemical or bio-
logical signalling activity of a diphenylacetylene retinoid or
retinoid-like structure. Furthermore, we have previously shown
that retinoid signalling activity can be completely eliminated
when the compound is of a length greater than EC23/ATRA and,
hence, given that DC324 and DC473 t this non-retinoid
structural criterion, we can be condent that the photo-
activated cell killing activity is not related to retinoid signalling
processes.21
In order to identify whether DC324 and DC473 directly cause
the formation of a specic ROS upon photoactivation, we per-
formed a variety of cuvette-based photophysical experiments
involving solutions of the compounds dissolved in a range of
oxygen saturated solvents, at various concentrations, with irra-
diation at both absorption maxima (experimental details in
ESI†). These included 1O2 sensitisation and phosphorescence
detection thereof, hydroxyl radical detection by absorption
measurements of added methylene blue, peroxyl radical
Fig. 5 (A) HaCaT keratinocytes treated with 1 mM DC324 (green) and
co-stained with MitoTracker Red (red). Scale bars equal 50 mm. (B)
Peak emission wavelength of DC324 in regions of interest (ROI) of
cells, with excitation at 405 nm. (C) ROI 1, green circle marks area distal
to nuclear membrane (lmax ¼ 490 nm) and ROI 2, blue circle, marks
area adjacent to nucleus (lmax ¼ 460 nm). Average emission wave-
length for red square was calculated (Average ROI lmax ¼ 475 nm).
Fig. 6 Detection of ﬂuorescence produced by ROS reactive dye,
CellRox in HaCaT keratinocytes treated with 1 mM DC324 or a DMSO
control. Scale bars equal 25 mm.
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detection by uorescence measurements of added rhodamine
6G, and hydrogen peroxide detection by chemiluminescence of
added luminol in the presence of a cobalt(II) catalyst (the latter
three types of experiment were carried out with the addition of
H2O to allow for facile formation of ROS from H2O). None of
these experiments returned a positive result. Furthermore,
there was no evidence, either through experimental or theo-
retical means, that the compounds are capable of generating
triplet excited states to any signicant extent.
Given the fact that we can, nevertheless, detect ROS upon
photoexcitation of DC324 and DC473 in cells using CellRox, it is
clear that an alternative ROS generation mechanism may be
taking place. This could involve changes in the excited state
properties of DC324 and DC473 and thus ROS formation by
direct association with a second species of cellular origin, or
that the photosensitising process involves sensitisation of
another species by interaction with the compounds upon light
activation. Such complex excited state modes of action would be
in line with our previous observation that, in an environment
where hydrogen bonding is possible, i.e. in polar solvents, the
excited state lifetime decay is complicated by a secondary
process starting at around 500 ps aer light excitation. Alter-
natively, when bound to a cellular membrane (e.g. mitochon-
drial), a conformational change in the photoexcited state of the
compound may induce signicant disruption of this membrane
and, therefore, the release of ROS as a biological response to
this cellular stress. In either case, our experiments clearly show
that the processes responsible for the observed cell death upon
photoexcitation of the compounds are not trivial.
We next employed RNA sequencing to provide information
on the biological and cellular responses that occur following in
cellulo photoactivation of the compounds. This higher level
approach enables ‘cause-and-eﬀect’ examination of the genes
and genetic pathways that are regulated in response to a stim-
ulus. Keratinocytes were treated with 1 mM DC473 for 4 hours
and were subsequently irradiated with UV-A (363–385 nm) light
for 1 minute. Aer 1 hour, RNA was collected from cells that had
been DC473-treated and irradiated, and from corresponding
DMSO-treated and DC473-treated, non-irradiated controls.
Gene set enrichment pathway analysis (see ESI†) of these RNA
samples indicated that, among other eﬀects, genetic responses
towards the presence of oxygen species were signicantly
upregulated when cells treated with DC473 were irradiated in
comparison to those of non-irradiated DC473-treated cells, and
both irradiated and non-irradiated DMSO-treated cells.
Responses towards the generation of nitrogenous compounds
were also evident, perhaps indicating the generation of nitric
oxide – a radical species that is heavily implicated in oxidative
stress pathways resulting from PDT.41,42 Furthermore, gene
regulatory pathways implicated in cell death processes were
only upregulated in the irradiated, DC473-treated cells. While
these experiments do not provide a precise molecular under-
standing of the reactive species that are generated, they do
provide strong and, in many respects, more direct evidence that
oxygen-containing species (and other nitrogenous species) are
produced upon in cellulo photoactivation of DC324 and DC473,
and that this phenomenon is likely to be the cause or at least
related directly to the observed cell death activity.
In vitro cultured epithelial, mesenchymal and colorectal (see
ESI†) cancer cells were next treated with a range of concentra-
tions of DC324, and a variety of experiments were conducted in
order to further quantify and characterise the observed light-
activated cytotoxic activity. In all these human cell lines, irra-
diation with either broadband UV-A (363–385 nm) or a mono-
chromatic 405 nm light source induced rapid cell death.
Furthermore, cell death was also observed when the compound
was irradiated at the corresponding two-photon absorption
wavelengths (800 nm), a particularly important property, as this
enables deeper tissue penetration (see ESI† for irradiation
images).43 It was further found that the cell death timeline could
Fig. 7 (A) Chemical structure of synthetic retinoid, EC23. (B) Quantitation of relative ﬂuorescence of CellRox before and after irradiation using
a 405 nm laser. The relative ﬂuorescence intensity was calculated in the region of interest (ROI, yellow box) at each time point and data graphed
using box-whisker plot. Graph coloured lines denote sample mean (n ¼ 11, DC324; n ¼ 3, EC23; n ¼ 3, negative) from 2 experimental replicates
for each treatment (red ¼ DC324, pink ¼ EC23, blue ¼ negative). Time 0 equals time of irradiation. Increased ﬂuorescence intensity in DC324-
treated cells was signiﬁcant as determined by one-way ANOVA (p < 0.001). Scale bars equal 50 mm.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 4673–4683 | 4677
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be modulated by varying the irradiation area, photon ux and
compound concentration. Fig. 8A illustrates that only the area
which received UV-A irradiation was destroyed, highlighting
that the cell-killing activity of the compounds is a light-
activated eﬀect, rather than one of general cytotoxicity.
Furthermore, the amount of energy supplied was important;
stronger irradiation per unit area expedited and increased the
extent of cell death (Fig. 8B). The cytotoxic eﬀect of the
compound was also characterised by a dose–response rela-
tionship between the cell viability and the treatment
concentration. Accordingly, we determined an EC50, based on
the average viable fraction of the epithelial cellular population
24 hours aer the initial irradiation event, of 0.20  0.01 mM
(Fig. 8C). The time required to induce cell death, and the
change in physiology, were also signicantly aﬀected by
compound concentration; i.e. irradiated cells exposed to the
higher concentrations tested (10 mM) induced necrosis-like
cell death in less than 60 seconds whilst cells exposed to
lower concentrations (e.g. 1 mM) showed an initial cell
membrane blebbing associated with cell apoptosis. Cell loss
was rapid, and maximal impact on cell viability was detected
approximately 400 minutes aer the initial irradiation event.
Importantly, cells exposed to the compound without irradia-
tion, or irradiation treatment alone, had no impact on cell
viability. These physiological and morphological changes are
consistent with cell death in response to the presence of
signicant amounts of ROS;44 however, given the apparent
inability for DC324 and DC473 to access triplet states that
could lead to the generation of ROS through the paradigm set
out by the porphyrins and other similar compounds,5 it is
clear that an alternative cytotoxic mechanism may be oper-
ating. Whether this eﬀect is achieved through sensitisation of
a second species by the photoactivated compound or, for
example, through disruption of the membrane/organelle(s)
which the compound is bound to or via another biological
response is unclear, and the enormous complexity of
a cellular system makes interrogation of this eﬀect inherently
diﬃcult. Nonetheless, as an orthogonal means for the
generation of a photodynamic therapeutic eﬀect, the unique
activity of DC324 and DC473 is highly compelling and of great
potential utility.
2.4 In vivo characterisation
To test the light-activated cytotoxic activity in an in vivo context,
48 hour old wild type zebrash embryos were exposed to 1 mM
DC324 for 2 hours, then transferred to E3 water without the
compound and incubated for 4 hours before irradiation.
Embryos irradiated (UV-A; 28 J cm2) in the developing tail
region showed evidence of cell death in the irradiated area but
not in adjacent regions.45 Following irradiation, nuclei became
distended and irregular in shape, a common characteristic of
nuclear apoptosis (Fig. 9).46 Together, these data clearly show
Fig. 8 (A) Phase contrast image of conﬂuent sheet of HaCaT epithelial cells exposed to 10 mM DC324 and the righthand area of the ﬁeld
irradiated with UV-A. Image captured 10 minutes post irradiation; note that cell death occurred only in the irradiated zone. Scale bars equal 100
mm. (B) Cell viability after irradiation with varying UV-A doses. Dose–response curves have been ﬁtted to the data in a box-whisker plot graph
using 4 experimental replicates (n ¼ 4). Statistical signiﬁcance was determined by one-way ANOVA (p < 0.0001) and Dunnett's multiple
comparison test comparing individual dose response curves to unirradiated controls (0 J cm2). The energy ﬂuence of 14, 28 and 42 J cm2 were
considered statistically signiﬁcant with p values of 0.0034, 0.0002 and <0.0001, respectively. (C) The average viable fraction of HaCaT epithelial
cellular populations 24 hours after an initial 60 second UV-exposure, as a function of the concentration of compound administered. A non-linear
regression curve is ﬁtted to the data (experimental replicates, n ¼ 3; R2 ¼ 0.99).
Fig. 9 48 hour wild-type zebraﬁsh embryo treated with 1 mM DC324
for 2 hours prior and the tail irradiated with 42 J cm2 of UV-A (time ¼
0 minutes); phase contrast images captured at the time of irradiation
(A/B) and 40 minutes after irradiation (C).
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that DC324 and DC473 have the potential to act as a potent
modality for the destruction of tissue in vitro and in vivo through
a light-activated cytotoxic eﬀect.
3 Conclusions
A class of small, organic, conjugated compounds, essentially
homologues of synthetic retinoids, show clear potential as
a novel photosensitising agent. DC324 and DC473 possess
much more ‘drug-like’ molecular weights and structures in
comparison to existing photosensitisers and a thorough bio-
logical characterisation has exemplied the ability for these
compounds to elicit cytotoxic activity, ostensibly through
bringing about robust intracellular ROS production following
UV-A or violet light absorption, or corresponding two-photon
absorption via near-IR irradiation. While UV-based photody-
namic therapies have typically seen only limited use in the
past,47,48 in more recent years signicant advances in optical
and endoscope technology have enabled the production of
devices including low cost portable LED-based illumination
systems capable of precisely targeted irradiation at a specic
wavelength. These next generation optical devices are begin-
ning to see widespread use in the clinic and, hence, potentially
pave the way for a treatment modality involving UV-activated,
‘drug-like’ photosensitisers in previously impractical or
impossible treatment regimes. However, the two-photon
absorption ability of the compounds would also enable use in
contexts where UV-activation remains intractable, taking
advantage of the greater tissue penetration of near-IR irradia-
tion. Furthermore, the modular structures of DC324 and DC473
could be modied in further studies to incorporate targeting
mechanisms, such as conjugation to an antibody to enable
specic localisation to diseased tissues, or to another small
molecule to inuence subcellular localisation. The small
molecular footprint of these novel photosensitisers would likely
have a negligible eﬀect on the eﬃcacy of these targeting
modalities, which is oen not the case, for example, with
antibody-conjugated porphyrin-based photosensitisers.49,50
Hence, the advantages of this new class of small, adaptable
organic PDT agent, which is highly cell-permeable, potent and
appears to exhibit a unique mode-of-action, could prove to be
the key to realising the rich potential PDT has for tackling
a wide range of disease treatment applications which, to date,
has been severely limited by the inadequate properties of
existing photosensitisers.
4 Experimental
4.1 General synthetic information
Reagents were purchased from Sigma-Aldrich, Acros Organics,
Alfa-Aesar and Fluorochem. Reagents were puried, if required,
by recrystallisation or distillation/sublimation under vacuum.
Solvents were used as supplied from Fisher Scientic or Sigma
Aldrich, and dried before use if required with appropriate
drying agents or using an Innovative Technologies Inc. Solvent
Purication System. Thin-layer chromatography (TLC) was
conducted using Merck Millipore silica gel 60G F254 25
glassplates and/or TLC-PET foils of aluminium oxide with
uorescent indicator 254 nm (40  80 mm) with visualisation
by UV lamp or appropriate staining agents. Flash column
chromatography was performed using SiO2 from Sigma-Aldrich
(230–400 mesh, 40–63 mM, 60 A˚), or activated neutral
aluminium oxide (alumina) from Sigma-Aldrich, andmonitored
using TLC. Sublimation/distillation was performed using
a Buchi Glass Oven B-585 Kugelrohr operating at a pressure
between 0.2 and 2.0 torr. NMR spectra were recorded using
Varian VNMRS-700, Varian VNMRS-600, Bruker Avance-400 or
Varian Mercury-400 spectrometers operating at ambient probe
temperature. NMR peaks are reported as singlet (s), doublet (d),
triplet (t), quartet (q), broad (br), septet (sept), combinations
thereof, or as a multiplet (m), with reference to the following
deuterated solvent signals: CDCl3 (
1H ¼ 7.26 ppm, 13C ¼ 77.23
ppm), (CD3)2SO (
1H ¼ 2.50 ppm, 13C ¼ 39.50 ppm). ESMS was
performed using a TQD (Waters Ltd., UK) mass spectrometer
with an Acquity UPLC (Waters Ltd., UK), and accurate mass
measurements were obtained using a QtoF Premier mass
spectrometer with an Acquity UPLC (Waters Ltd., UK). ASAP
measurements were performed using an LCT Premier XE mass
spectrometer and an Acquity UPLC (Waters Ltd., UK). GCMS
was performed with a QP2010-Ultra (Shimadzu) GCMS. IR
spectra were recorded using a Perkin Elmer FTIR spectrometer.
Melting points were obtained using a Gallenkamp melting
point apparatus and are uncorrected. Elemental analysis was
conducted using an Exeter Analytical CE-440 analyser.
4.2 Synthesis
4-Iodobenzenediazonium tetrauoroborate, 1. 4-Iodoaniline
(10.95 g, 50 mmol) was added to tetrauoroboric acid (48% in
H2O, 25 mL), and the suspension was cooled to 0 C before
a solution of NaNO2 (3.79 g, 55 mmol) in H2O (13.7 mL) was
added dropwise with vigorous stirring so as to maintain the
internal temperature below 5 C. Aer addition, the suspension
was further stirred for 1 h at 0 C before the precipitated solid
was isolated by ltration, washed with cold MeOH and dried to
give a crude brown solid. This was dissolved in a minimal
amount of acetone (ca. 55 mL), to which Et2O was slowly added
to precipitate a yellow solid. This was ltered, washed with cold
Et2O and dried to give compound 1 as a pale yellow solid (13.1 g,
83%): mp ¼ 106–108 C (decomposition); 1H NMR (700 MHz,
(CD3)2SO) d 8.35 (d, J ¼ 9.0 Hz, 2H), 8.43 (d, J ¼ 9.0 Hz, 2H); 13C
{1H} NMR (151 MHz, (CD3)2SO) d 113.6, 115.1, 132.8, 140.2; IR
(ATR) vmax/cm
1 3090w, 2282s, 1548m, 1461w, 824s, 523m; MS
(EI): m/z ¼ 204 [M  N2]+; found: C, 22.83; H, 1.30; N, 8.83, calc.
for C6H4BF4IN2: C, 22.67; H, 1.27; N, 8.81%.51
Methyl (2E)-3-(4-iodophenyl)prop-2-enoate, 2. Pd(OAc)2
(0.138 g, 0.61 mmol), CaCO3 (2.40 g, 24.0 mmol) and compound
1 (5.54 g, 17.4 mmol) were suspended in MeOH (60 mL). Methyl
acrylate (2.16 mL, 24.0 mmol) was added, and the suspension
was stirred vigorously for 1.5 h at RT. The solution was diluted
with DCM, ltered through Celite® and evaporated to give
a crude light brown solid (6.3 g). This was puried by SiO2
chromatography (hexane : DCM, 1 : 1, as eluent) to give
compound 2 as a white solid (3.74 g, 75%): mp¼ 119–120 C; 1H
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 4673–4683 | 4679
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
M
ar
ch
 2
01
9.
 D
ow
nl
oa
de
d 
on
 4
/2
4/
20
19
 4
:3
0:
32
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
NMR (600 MHz, CDCl3) d 3.81 (s, 3H), 6.44 (d, J ¼ 16.0 Hz, 1H),
7.24 (d, J ¼ 8.4 Hz, 2H), 7.60 (d, J ¼ 16.0 Hz, 1H), 7.73 (d, J ¼
8.4 Hz, 2H); 13C{1H} NMR (151 MHz, CDCl3) d 52.0, 96.7, 118.8,
129.7, 134.1, 138.3, 143.8, 167.3; IR (ATR) vmax/cm
1 3080w,
3000w, 2850w, 1708s, 1636m, 1580m, 1483m, 815s, 493m;
MS(ES):m/z¼ 289 [M + H]+; HRMS (ES) calcd for C10H10IO2 [M +
H]+: 288.9726, found 288.9733; found: C, 41.86; H, 3.14. Calc. for
C10H9IO2: C, 41.96; H, 3.15%.52
Methyl (2E)-3-4-[2-(trimethylsilyl)ethynyl]phenylprop-2-
enoate, 3. An oven-dried Schlenk ask was evacuated under
reduced pressure and relled with Ar, before Pd(PPh3)2Cl2
(0.217 g, 0.31 mmol), CuI (0.060 g, 0.31 mmol) and compound 2
(3.57 g, 12.38 mmol) were added and the ask sealed with
a septum. Et3N (80 mL) and trimethylsilylacetylene (1.76 mL,
12.44 mmol) were added and the ask evacuated/lled with Ar
again (3). The mixture was stirred at RT for 16 h. The solution
was diluted with Et2O, passed through Celite®/SiO2 under
vacuum, and evaporated to give a crude brown solid (4.5 g). This
was puried by SiO2 chromatography (hexane : EtOAc, 9 : 1, as
eluent) to give compound 3 as a white solid (2.65 g, 83%): mp ¼
76–78 C; 1H NMR (600 MHz, CDCl3) d 0.26 (s, 9H), 3.81 (s, 3H),
6.43 (d, J ¼ 16.0 Hz, 1H), 7.43–7.48 (m, 4H), 7.65 (d, J ¼ 16.0 Hz,
1H); 13C{1H} NMR (151 MHz; CDCl3) d 0.1, 52.0, 96.9, 104.7,
118.8, 125.2, 128.1, 132.6, 134.5, 144.1, 167.4; IR (ATR) vmax/
cm1 2952w, 2898w, 2156w, 1715s, 1634m, 1599w, 1442m,
1171s, 840s; MS(ES): m/z ¼ 259 [M + H]+; HRMS (ES) calcd for
C15H19SiO2 [M + H]
+: 259.1154, found 259.1147.
Methyl (2E)-3-(4-ethynylphenyl)prop-2-enoate, 4. Compound
3 (2.21 g, 8.55 mmol) was dissolved in THF (25 mL), and cooled
to 20 C. Tetrabutylammonium uoride (1.0 M in THF) (8.98
mL, 8.98 mmol) was then added dropwise and the resultant
solution stirred at 20 C for 1 h, aer which H2O was added,
and the solution extracted with EtOAc (3). The organics were
washed with brine, dried (MgSO4) and evaporated to give
a crude brown solid. This was puried by SiO2 chromatography
(hexane : EtOAc, 9 : 1, as eluent) to give compound 4 as a white
solid (1.52 g, 95%): mp ¼ 93–95 C; 1H NMR (600 MHz; CDCl3)
d 3.18 (s, 1H), 3.81 (s, 3H), 6.44 (d, J ¼ 16.0 Hz, 1H), 7.46–7.51
(m, 4H), 7.66 (d, J ¼ 16.0 Hz, 1H); 13C{1H} NMR (151 MHz;
CDCl3) d 52.0, 79.4, 83.3, 119.1, 124.2, 128.1, 132.8, 134.9, 143.9,
167.4; IR (ATR) vmax/cm
1 3260m, 2996w, 2946w, 2108w, 1700s,
1634m, 1554m, 1431m, 1206s, 831s; MS (EI): m/z ¼ 186 [M]+;
found: C, 77.40; H, 5.37. Calc. for C12H10O2: C, 77.40; H,
5.41%.53 Note: compound 4 can also be puried by Kugelrohr
sublimation under vacuum (115–125 C, 0.8 torr).
6-Iodo-4,4-dimethyl-1-(propan-2-yl)-1,2,3,4-
tetrahydroquinoline, 5. Full synthetic details for the synthesis
of donor tetrahydroquinoline 5 are available in a previous
report.34
(2E)-3-(4-{2-[4,4-Dimethyl-1-(propan-2-yl)-1,2,3,4-
tetrahydroquinolin-6-yl]-ethynyl}phenyl)prop-2-enoic acid,
DC324. Compound 5 (0.61 g, 1.85 mmol) was dissolved in Et3N
(12 mL), and the resultant solution was degassed by sonication
under vacuum, before the atmosphere was replaced with Ar
(5). Pd(PPh3)2Cl2 (0.13 g, 0.185 mmol), CuI (0.035 g, 0.185
mmol) and compound 4 (0.36 g, 1.94 mmol) were then added
under Ar. The resultant suspension was stirred at RT for 72 h.
The suspension was diluted with hexane and passed through
a Celite®/SiO2 plug (eluting with hexane, then hexane : EtOAc
(8 : 2)). The extracts were washed with sat. NH4Cl (3) and
brine, dried (MgSO4) and evaporated to give the intermediate
ester as an orange solid (0.7 g). This was dissolved in THF (20
mL), and 20% NaOH (2 mL) was added, and the resultant
solution was stirred at reux for 40 h. The mixture was cooled,
acidied to pH 1 with 5% HCl, diluted with EtOAc, washed with
sat. NH4Cl, H2O and brine, dried (MgSO4) and evaporated to
give a crude yellow solid which was recrystallised fromMeOH to
give DC324 as an orange crystalline solid (0.46 g, 67% over three
steps): mp ¼ 214–215 C (decomposition); 1H NMR (700 MHz;
(CD3)2SO) d 1.16 (d, J ¼ 6.7 Hz, 6H), 1.22 (s, 6H, H11/12), 1.63 (t,
J ¼ 6.0 Hz, 2H), 3.18 (t, J ¼ 6.0 Hz, 2H), 4.14 (sept, J ¼ 6.7 Hz,
1H), 6.54 (d, J ¼ 16.0 Hz, 1H), 6.69 (d, J¼ 8.7 Hz, 1H), 7.17 (dd, J
¼ 8.7, 2.2 Hz, 1H), 7.29 (d, J ¼ 2.2 Hz, 1H), 7.46–7.51 (m, 2H),
7.58 (d, J ¼ 16.0 Hz, 1H), 7.66–7.72 (m, 2H), 12.41 (s, 1H); 13C
{1H} NMR (176 MHz; (CD3)2SO) d 18.6, 29.7, 31.6, 35.9, 36.1,
46.6, 86.9, 94.0, 106.8, 110.5, 119.5, 125.2, 128.4, 128.8, 130.6,
131.1, 131.2, 133.3, 143.0, 144.5, 167.5; vmax/cm
1 2968w,
2929w, 2870w, 2195m, 1683s, 1622m, 1594s, 1514s, 1421m,
1187m, 837m; MS(ES): m/z ¼ 374 [M + H]+; HRMS (ES) calcd for
C25H28NO2 [M + H]
+: 374.2120, found 374.2118; found: C, 79.90;
H, 7.27; N, 3.65. Calc. for C25H27NO2: C, 80.40; H, 7.29; N,
3.75%.
4.3 General photophysical information
UV-visible absorption spectra were obtained on an Agilent
1100 Series Diode Array spectrophotometer using standard
1 cm path length quartz cells. Excitation and emission spectra
were recorded on an Edinburgh Instruments FLSP920 spec-
trophotometer, equipped with a 450 W xenon arc lamp,
double monochromators for the excitation and emission
pathways, a red-sensitive photomultiplier (PMT-R928) and
a near-IR PMT as detectors, or on a Horiba Jobin-Yvon Fluo-
romax 3 spectrophotometer with single monochromators for
the excitation and emission pathways. The excitation and
emission spectra were corrected using the standard correc-
tions supplied by the manufacturers for the spectral power of
the excitation source and the sensitivity of the detector. The
quantum yields were measured by use of integrating spheres
with either an Edinburgh Instruments FLSP920 spectropho-
tometer or the Horiba Jobin-Yvon Fluoromax 3 spectropho-
tometer. The luminescence lifetimes were measured using
a TCSPC module on an FLSP980 spectrometer equipped with
a high speed photomultiplier tube positioned aer a single
emission monochromator and operating with pulsed laser
diodes (376 or 274 nm, repetition rate 1–5 MHz, pulse width
ca. 200 ps, instrument response function ca. 500 ps). Decays
were recorded to 10 000 counts in the peak channel with
a record length of at least 1000 channels. The band-pass of the
monochromator was adjusted to give a signal count rate of
<20 kHz. Iterative reconvolution of the IRF with one decay
function and nonlinear least-squares analysis were used to
analyse the data. The quality of all decay ts was judged to be
satisfactory, based on the calculated values of the reduced X2
4680 | Chem. Sci., 2019, 10, 4673–4683 This journal is © The Royal Society of Chemistry 2019
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and Durbin–Watson parameters and visual inspection of the
weighted and autocorrelated residuals.
4.4 Computational details
Calculations (gas-phase) were performed with the ORCA 3.0.2
program suite.54 Geometry optimisations were carried out with
the B3LYP55–57 functional as implemented in ORCA, and
a frequency analysis ensuring that the optimized structures
correspond to energy minima. The def2-TZVP58,59 basis set was
used for all atoms together with the auxiliary basis set def2-
TZVP/J in order to accelerate the computations within the
framework of the RI approximation. van der Waals interactions
have been considered by an empirical dispersion correction
(Grimme-D3BJ).60,61 TD-DFT calculations for the rst 100 singlet
and triplet excited states were performed with the M06 func-
tional62 and the above mentioned basis sets. Representations of
electron density changes were produced with orca plot as
provided by ORCA 3.0.2 and with gOpenMol 3.00.63,64
4.5 Cells
HaCaT human epidermal keratinocytes were purchased from
a commercial supplier (Thermo Fisher) and primary human
dermal broblasts (HDF) were isolated from human patients
under ethical guidelines from National Research Ethics
Service.65 Both cell lines were cultured at 37 C/5% CO2 in
DMEM (Gibco cat. no. 10566, high glucose, GlutaMAX Supple-
ment) with 10% fetal calf serum and 1 penicillin/
streptomycin. For experimental procedures, cells were seeded
(1.2  104 to 5  104 per well) in 24-well or 6-well tissue culture
plates (Corning) or on single or 8-well chambered coverslips for
a minimum of 48 h prior to the start of an experiment. In some
experiments, HaCaT (2  104) and HDF (4  104) cells were co-
seeded in 8-well chambered coverslips. Cells were treated with
DC324 (stock concentration 10 mM dissolved in DMSO) at
a range of nal concentrations (0.001–10 mM) in media with
0.1% DMSO. As controls, cells were treated with 0.1% DMSO or
1 mM EC23, a compound with similar chemical structure to
DC324, but no (or negligible) absorption when excited by UV-A
or violet light wavelengths.18 Cells were treated with the
compound for 1–4 h before irradiation.
4.6 Imaging
Live and xed cells were imaged using a Zeiss 880 Laser Scan-
ning Confocal Microscope (LSCM) with Airyscan detection and
an environmental chamber at 37 C and 5% CO2. Fixed cells
were imaged at room temperature and in air. Samples were
excited with a 405 nm, 594 nm or 633 nm laser and imaged with
a Plan-Apochromat 63/1.4 Oil DIC M27 objective lens. For
irradiation-induced cell death experiments, cells were irradi-
ated and imaged on either the Zeiss 880 LSCM or a Zeiss Axio
Vert A1, wide eld uorescence microscope with environmental
control chamber using image corrected 10 or 20 objective
lenses designed for live cell imaging. UV-A ltered irradiation
(Axio Vert A1) was carried out using an OSRAM 1HBO 103W/2
100 watt mercury bulb using DAPI excitation lters with
a bandwidth of 335–385 nm and emission bandwidth of 420–
470 nm according to manufacturer's specication; 405 nm
irradiation (880 LSCM) was carried out with a 405 nm diode
laser. Excitation wavelengths for both microscopes were
conrmed by measuring the light spectrum with an Ocean
Optics USB 2000+ Spectrometer (see ESI†). The irradiation beam
was optically restricted to a limited region within the eld of
view for most experiments (see ESI†). A well-dened boundary
was achieved using a simple mask in the illumination optical
path for the wideeld measurements and using ROI scanning
for the laser measurements allowing for interrogation of irra-
diated and non-irradiated areas in the same eld of view. Cells
were imaged for up to 24 h on the microscope with environ-
mental controls.
4.7 MitoTracker® staining
DC324-treated cells, plated on coverslips, were incubated for
30 min with MitoTracker® Red (Thermo Fisher, cat. no.
M22425), prepared according to manufacturer's directions and
diluted in serum containing media (1 mL, 0.1 mM), then rinsed
twice with PBS (pH 7.2) before incubation and subsequent
xation in paraformaldehyde/PBS (PFA, 4%), for 5 min. Cells
were rinsed in PBS before mounting coverslips in a polyvinyl
alcohol mounting media.
4.8 ROS quantitation
Cells in separate wells were treated with DC324 or EC23 at 1 mM
concentration (0.1% DMSO) in media and incubated in a tissue
culture incubator. A negative control of 0.1% DMSO in media
was also used. Aer 2 h, CellRox (Sigma C10422 Deep Red 640/
665 nm) at a nal concentration of 5 mM was added to the cells
and further incubated for 30 min. Cells were then transferred to
the 37 C, 5% CO2 environmental chamber on the Zeiss 880
LCSM. To quantify ROS production detected by 633 nm excita-
tion of CellRox dye, background uorescence emission inten-
sities (655–675 nm) were captured rst in each experimental
eld for 5 min, then the eld was irradiated with 405 nm and
uorescence levels (655–675 nm) were captured for an addi-
tional 10 min following irradiation. Zeiss Zen Black and FIJI
imaging processing soware were used to calculate the ROI
relative uorescence intensity levels. A minimum of 3 experi-
mental replicates were performed for each treatment.
4.9 RNAseq and bioinformatics
HaCaT human keratinocyte cells were seeded at a density of 2
105 cells per well in an uncoated, 6-well tissue culture plate. 72 h
aer plating, when cells were approximately 80% conuent,
cells were treated with either 0.1%DMSO or 1 mMDC473 for 4 h,
then some samples were irradiated with UV-A (363–385 nm with
a peak at 371 nm; see ESI†) for 1 min. RNA was collected 1 h
aer irradiation and prepared for sequencing using a Qiagen
RNeasy Mini Kit with on-column DNaseI digestion. RNA
samples were quantied using the NanoDrop and uorometric
methods and the mRNA had RIN values of 8 and above. RNAseq
was performed by the sequencing facility at the Institute for
Genetic Medicine, Newcastle University.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 4673–4683 | 4681
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Illumina reads were aligned to the human reference genome
(GRCh38) using HISAT2 v.2.0.5.29. The alignments were
assembled and quantication performed using StringTie
v.1.3.4.30. The R package Ballgown v.2.6.0 was used for all
diﬀerential expression analysis. Results from using the list
of genes for diﬀerential expression (pval < 0.01) was
compared by gene set enrichment analysis (GSEA; http://
www.soware.broadinstitute.org/gsea/index.jsp) looking at
the ‘GO’ (gene ontology) gene sets (see ESI†). These show the
number of genes in each list which have a signicant overlap
with particular sets of genes.
4.10 Cell death quantitation and statistical analysis
Each well was allocated 4 set points where 3 points were sub-
jected to 1 min of UV irradiation in a specic rectangular zone.
The fourth zone was a control with no irradiation. Images were
captured at 30 min intervals for 24 h. Using ImageJ,66 time zero
and 24 h post irradiation numbers of viable and non-viable cells
were counted from the zone areas. The viable and non-viable
cell numbers for each time point were added together and the
viability percentage was calculated by dividing the viable cells
by the total cell count. The percentage of relative viability was
then calculated by dividing the 24 h time point by the zero time
point. Statistical signicance was calculated by one-way ANOVA
using GraphPad Prism 7 soware, Macintosh, GraphPad So-
ware, La Jolla California USA, http://www.graphpad.com.
4.11 Zebrash experiments
48 Hour, wild type zebrash embryos (Golden) were treated with
1 mM DC324 diluted in E3 water (5.0 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, 0.33 mM MgSO4) for 2 h.67 Embryos were then
transferred to fresh E3 water and incubated for a further 2 h
prior to irradiation. Embryos were anesthetised using buﬀered
MS222 solution (0.1%; pH 7.0; ethyl 3-aminobenzoate meth-
anesulfonate dissolved in E3 water and buﬀered with NaHCO3)
and then irradiated using the Axio Vert A1 system as described
above with 33 J cm2 of UV-A with appropriate environmental
controls. Phase contrast and uorescence images were captured
at the time of irradiation with only phase contrast imaged
captured at subsequent time points.
Conﬂicts of interest
A. W. and C. A. A. own shares of LightOx Limited, the company
licensed to pursue commercial applications of the novel
chemicals described in this manuscript.
Acknowledgements
D. R. C. thanks the EPSRC, BBSRC andHigh Force Research Ltd.
for doctoral funding. T. B. M. thanks the Julius-Maximilians-
Universita¨t Wu¨rzburg for support. A. K. N. thanks the Fulbright
Foundation for a Visiting Fulbright Scholarship. We thank Dr
R. M. Edkins for obtaining some of the optical spectra of DC324.
We thank Dr E. Pohl for helpful discussions and proof-reading.
Notes and references
1 K. M. Holmstro¨m and T. Finkel, Nat. Rev. Mol. Cell Biol.,
2014, 15, 411–421.
2 X. Zhao and K. Drlica, Curr. Opin. Microbiol., 2014, 21, 1–6.
3 D. E. J. G. J. Dolmans, D. Fukumura and R. K. Jain, Nat. Rev.
Cancer, 2003, 3, 380–387.
4 C. Schweitzer, Z. Mehrdad, A. Noll, E.-W. Grabner and
R. Schmidt, J. Phys. Chem. A, 2003, 107, 2192–2198.
5 R. Schmidt, Photochem. Photobiol., 2007, 82, 1161–1177.
6 P. R. Ogilby, Chem. Soc. Rev., 2010, 39, 3181–3209.
7 Y. L. Guo, S. Chakraborty, S. S. Rajan, R. Wang and F. Huang,
Stem Cells Dev., 2010, 19, 1321–1331.
8 Z. Guo, S. Kozlov, M. F. Lavin, M. D. Person and T. T. Paull,
Science, 2010, 330, 517–521.
9 K. Ito, A. Hirao, F. Arai, S. Matsuoka, K. Takubo,
I. Hamaguchi, K. Nomiyama, K. Hosokawa, K. Sakurada,
N. Nakagata, Y. Ikeda, T. W. Mak and T. Suda, Nature,
2004, 431, 997–1002.
10 N. Shirasu, S. O. Nam and M. Kuroki, Anticancer Res., 2013,
33, 2823–2831.
11 R. Bonnett, Chem. Soc. Rev., 1995, 24, 19–33.
12 J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe,
S. Verma, B. W. Pogue and T. Hasan, Chem. Rev., 2010,
110, 2795–2838.
13 B. C. Wilson, M. Olivo and G. Singh, Photochem. Photobiol.,
1997, 65, 166–176.
14 J. Zhang, C. Jiang, J. P. F. Longo, R. B. Azevedo, H. Zhang and
A. L. Muehlmann, Acta Pharm. Sin. B, 2018, 8, 137–146.
15 M. Wachowska, A. Muchowicz, M. Firczuk, M. Gabrysiak,
M. Winiarska, M. Wan´czyk, K. Bojarczuk and J. Golab,
Molecules, 2011, 16, 4140–4164.
16 A. Orenstein, G. Kostenich, L. Roitman, Y. Shechtman,
Y. Kopolovic, B. Ehrenberg and Z. Malik, Br. J. Cancer,
1996, 73, 937–944.
17 M. E. Bulina, D. M. Chudakov, O. V. Britanova,
Y. G. Yanushevich, D. B. Staroverov, T. V. Chepurnykh,
E. M. Merzlyak, M. A. Shkrob, S. Lukyanov and
K. A. Lukyanov, Nat. Biotechnol., 2006, 24, 95–99.
18 V. B. Christie, J. H. Barnard, A. S. Batsanov, C. E. Bridgens,
E. B. Cartmell, J. C. Collings, D. J. Maltman,
C. P. F. Redfern, T. B. Marder, S. Przyborski and
A. Whiting, Org. Biomol. Chem., 2008, 6, 3497–3507.
19 G. Zhou, D. M. Tams, T. B. Marder, R. Valentine, A. Whiting
and S. A. Przyborski, Org. Biomol. Chem., 2013, 11, 2323–2334.
20 J. H. Barnard, J. C. Collings, A. Whiting, S. A. Przyborski and
T. B. Marder, Chem.–Eur. J., 2009, 15, 11430–11442.
21 G. Clemens, K. R. Flower, P. Gardner, A. P. Henderson,
J. P. Knowles, T. B. Marder, A. Whiting and S. Przyborski,
Mol. BioSyst., 2013, 9, 3124–3134.
22 G. Clemens, K. R. Flower, A. P. Henderson, A. Whiting,
S. A. Przyborski, M. Jimenez-Hernandez, F. Ball, P. Bassan,
G. Cinque and P. Gardner, Mol. BioSyst., 2013, 9, 677–692.
23 H. Haﬀez, D. R. Chisholm, R. Valentine, E. Pohl,
C. P. F. Redfern and A. Whiting, Med. Chem. Commun.,
2017, 8, 578–592.
4682 | Chem. Sci., 2019, 10, 4673–4683 This journal is © The Royal Society of Chemistry 2019
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
M
ar
ch
 2
01
9.
 D
ow
nl
oa
de
d 
on
 4
/2
4/
20
19
 4
:3
0:
32
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
24 H. Haﬀez, T. Khatib, P. McCaﬀery, S. Przyborski, C. Redfern
and A. Whiting, Mol. Neurobiol., 2018, 55, 1942–1950.
25 J. B. Bauer, W. P. Lippert, S. Do¨rrich, D. Tebbe, C. Burschka,
V. B. Christie, D. M. Tams, A. P. Henderson, B. A. Murray,
T. B. Marder, S. A. Przyborski and R. Tacke,
ChemMedChem, 2011, 6, 1509–1517.
26 T. B. Marder and A. Whiting, UK patent application no.
GB1417957.6, 2014.
27 C. A. Ambler, D. R. Chisholm and A. Whiting, UK patent
application no. GB1613712.7, 2016.
28 J. C. Collings, A. C. Parsons, L. Porre`s, A. Beeby,
A. S. Batsanov, J. A. K. Howard, D. P. Lydon, P. J. Low,
I. J. S. Fairlamb and T. B. Marder, Chem. Commun., 2005,
2666–2668.
29 C. Dehu, F. Meyers and J. L. Bredas, J. Am. Chem. Soc., 1993,
115, 6198–6206.
30 M. Biswas, P. Nguyen, T. B. Marder and L. R. Khundkar, J.
Phys. Chem. A, 1997, 101, 1689–1695.
31 P. Nguyen, Z. Yuan, L. Agocs, G. Lesley and T. B. Marder,
Inorg. Chim. Acta, 1994, 220, 289–296.
32 P. Nguyen, G. Lesley, T. B. Marder, I. Ledoux and J. Zyss,
Chem. Mater., 1997, 9, 406–408.
33 L. R. Khundkar, A. E. Stiegman and J. W. Perry, J. Phys.
Chem., 1990, 94, 1224–1226.
34 D. R. Chisholm, G.-L. Zhou, E. Pohl, R. Valentine and
A. Whiting, Beilstein J. Org. Chem., 2016, 12, 1851–1862.
35 J. H. Barnard, PhD thesis, Durham University, 2010.
36 J. G. Taylor, A. V. Moro and C. R. D. Correia, Eur. J. Org.
Chem., 2011, 1403–1428.
37 R. Chinchilla and C. Na´jera, Chem. Soc. Rev., 2011, 40, 5084–
5121.
38 J. Gala De Pablo, D. R. Chisholm, A. Steﬀen, A. K. Nelson,
C. Mahler, T. B. Marder, S. A. Peyman, J. M. Girkin,
C. A. Ambler, A. Whiting and S. D. Evans, Analyst, 2018,
143, 6113–6120.
39 J. C. Collings, S.-Y. Poon, C. Le Droumaguet, M. Charlot,
C. Katan, L.-O. Pa˚lsson, A. Beeby, J. A. Mosely,
H. M. Kaiser, D. Kaufmann, W.-Y. Wong, M. Blanchard-
Desce and T. B. Marder, Chem.–Eur. J., 2009, 15, 198–208.
40 H. Choi, Z. Yang and J. C. Weisshaar, Proc. Natl. Acad. Sci. U.
S. A., 2015, 112, E303–E310.
41 K. J. Reeves, M. W. R. Reed and N. J. Brown, J. Photochem.
Photobiol., B, 2009, 95, 141–147.
42 R. P. Patel, J. McAndrew, H. Sellak, C. R. White, H. Jo,
B. A. Freeman and V. M. Darley-Usmar, Biochim. Biophys.
Acta, 1999, 1411, 385–400.
43 E. A. Wachter, W. G. Fisher, C. Dees, M. G. Petersen and
M. Panjehpour, Biomedical Optical Spectroscopy and
Diagnostics/Therapeutic Laser Applications, OSA Trends in
Optics and Photonics Series, Optical Society of America,
Orlando, Florida, USA, Orlando, Florida, 1998.
44 M. Redza-Dutordoir and D. A. Averill-Bates, Biochim. Biophys.
Acta, 2016, 1863, 2977–2992.
45 C. Buckley, M. T. Carvalho, L. K. Young, S. A. Rider,
C. McFadden, C. Berlage, R. F. Verdon, J. M. Taylor,
J. M. Girkin and J. J. Mullins, Sci. Rep., 2017, 7, 5096.
46 V. L. Johnson, S. C. Ko, T. H. Holmstrom, J. E. Eriksson and
S. C. Chow, J. Cell Sci., 2000, 113, 2941–2953.
47 J. Jose´ Serrano-Pe´rez, M. Mercha´n and L. Serrano-Andre´s, J.
Phys. Chem. B, 2008, 112, 14002–14010.
48 F. Almutawa, L. Thalib, D. Hekman, Q. Sun, I. Hamzavi and
H. W. Lim, Photodermatol., Photoimmunol. Photomed., 2015,
31, 5–14.
49 G. A. M. S. van Dongen, G. W. M. Visser and
M. B. Vrouenraets, Adv. Drug Delivery Rev., 2004, 56, 31–52.
50 P. M. R. Pereira, B. Korsak, B. Sarmento, R. J. Schneider,
R. Fernandes and J. P. C. Tome´, Org. Biomol. Chem., 2015,
13, 2518–2529.
51 B. A. Haag, Z.-G. Zhang, J.-S. Li and P. Knochel, Angew.
Chem., Int. Ed., 2010, 49, 9513–9516.
52 H. Brunner, N. Le Cousturier de Courcy and J.-P. Geneˆt,
Tetrahedron Lett., 1999, 40, 4815–4818.
53 E. Christiansen, M. E. Due-Hansen, C. Urban,
M. Grundmann, J. Schmidt, S. V. F. Hansen, B. D. Hudson,
M. Zaibi, S. B. Markussen, E. Hagesaether, G. Milligan,
M. A. Cawthorne, E. Kostenis, M. U. Kassack and T. Ulven,
J. Med. Chem., 2013, 56, 982–992.
54 F. Neese, WIREs Comput. Mol. Sci., 2012, 2, 73–78.
55 A. Becke, J. Chem. Phys., 1993, 98, 5648–5652.
56 C. Lee, W. Yang and R. Parr, Phys. Rev. B: Condens. Matter
Mater. Phys., 1988, 37, 785–789.
57 P. J. Stephens, F. J. Devlin, C. F. Chabalowski and
M. J. Frisch, J. Phys. Chem., 1994, 98, 11623–11627.
58 A. Scha¨fer, C. Huber and R. Ahlrichs, J. Chem. Phys., 1994,
100, 5829–5835.
59 F. Weigend and R. Ahlrichs, Phys. Chem. Chem. Phys., 2005,
7, 3297–3305.
60 S. Grimme, J. Antony, S. Ehrlich and H. Krieg, J. Chem. Phys.,
2010, 132, 154104.
61 S. Grimme, S. Ehrlich and L. Goerigk, J. Comput. Chem.,
2011, 32, 1456–1465.
62 Y. Zhao and D. G. Truhlar, Theor. Chem. Acc., 2008, 120, 215–
241.
63 L. Laaksonen, J. Mol. Graphics, 1992, 10, 33–34.
64 D. L. Bergman, L. Laaksonen and A. Laaksonen, J. Mol.
Graphics Modell., 1997, 15, 301–306.
65 K. Gledhill, A. Gardner and C. A. Jahoda, Isolation and
Establishment of Hair Follicle Dermal Papilla Cell Cultures,
Humana Press, Totowa, NJ, 2013, vol. 989, pp. 285–292.
66 C. A. Schneider, W. S. Rasband and K. W. Eliceiri, Nat.
Methods, 2012, 9, 671–675.
67 C. B. Kimmel, W. W. Ballard, S. R. Kimmel, B. Ullmann and
T. F. Schilling, Dev. Dyn., 1995, 203, 253–310.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 4673–4683 | 4683
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
M
ar
ch
 2
01
9.
 D
ow
nl
oa
de
d 
on
 4
/2
4/
20
19
 4
:3
0:
32
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
